Annovis Bio Inc (ANVS)

Over the past six months, Annovis Bio announced encouraging biomarker results from its Phase 2/3 AD trial and closed a $6.0 million registered direct offering in October 2025. In November 2025, the company provided corporate updates and reported its third-quarter 2025 financial results, noting that its pivotal Phase 3 Alzheimer's study had achieved full activation across all clinical sites. In February 2026, the company secured DSMB approval to advance its pivotal Phase 3 trial of Buntanetap in Alzheimer's Disease and initiated a Phase II/III open-label extension study in Parkinson's disease. In March 2026, Annovis announced two presentations at the AD/PD™ 2026 International Conference and provided corporate updates along with fiscal year 2025 financial results, and a historical review of Buntanetap was published in The Scientist. In April 2026, Annovis secured a U.S. Patent for Buntanetap for the prevention and treatment of neurological injuries caused by brain infections and partnered with NeuroRPM to integrate AI-powered digital biomarker technology into its Parkinson's Disease study. Annovis closed an underwritten public offering, raising approximately $10 million in gross proceeds, which is expected to extend its cash runway through Q2 2027. The stock price on April 10, 2026, was $1.59 per share, showing a 22.31% increase from April 11, 2025, when it was $1.30 per share, with a modest gain of +0.4% over the past six months and a 52-week trading range between $1.11 and $5.50.

As a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, the demand for Annovis Bio, Inc.'s products and services is primarily driven by the prevalence of these diseases and the progress of its clinical trials. There is no indication of typical seasonal demand patterns affecting its products or services.

Annovis Bio, Inc. is a late-stage clinical drug platform company focused on developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The company develops drugs that target multiple neurotoxic proteins simultaneously to restore axonal and synaptic activity, aiming to address both cognitive decline and motor dysfunction. Its lead product candidate, Buntanetap, is in Phase 2/3 clinical trials for Alzheimer's disease, Phase 3 for Parkinson's disease, and Phase 2 for Lewy Body Dementia. ANVS405 is in Phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke, and ANVS301 has completed Phase 1 clinical trials and is being developed to enhance cognitive capabilities in the later stages of Alzheimer's disease and dementia.

Annovis Bio, Inc. is headquartered in Malvern, Pennsylvania, United States. The company's pivotal Phase 3 Alzheimer's disease study is actively enrolling participants across clinical sites throughout the U.S.

In the past year, Annovis Bio has seen positive developments, including statistically significant data from its Phase II/III Alzheimer's study, promising data from the Phase III study of buntanetap in Parkinson's disease patients, a historical review of Buntanetap published in The Scientist, securing a U.S. Patent for Buntanetap for its use in preventing and treating neurological injuries caused by brain infections, and a partnership with NeuroRPM to deploy AI-powered digital biomarker technology in a Parkinson's Disease clinical trial. Annovis Bio is also recognized for its capital efficiency, having zero debt and multiple global patents extending into the 2040s. However, concerns have been raised regarding the company's cash burn rate and the need for careful business growth, and an AI-powered stock analysis model assigned a "Sell" rating.

Annovis Bio's ownership structure includes institutional, insider, and public/individual investors. Institutional investors hold approximately between 8.42% and 18.58% of the company's stock, with 58 institutional owners holding a total of 4,269,564 shares. Major institutional owners include Vanguard Group Inc, Marshall Wace, Llp, Two Sigma Investments, Lp, Susquehanna International Group, Llp, Jane Street Group, Llc, Geode Capital Management, Llc, Citadel Advisors Llc, D.a. Davidson & Co., BlackRock, Inc., Northern Trust Corp, and State Street Corp. Insider ownership stands at approximately 15.17% to 15.22%. Individual investors, along with public companies, account for roughly 76.36% of the ownership, with Michael B. Hoffman owning the most shares among individual investors.